为什么部分患者停用新型失眠药 lemborexant:网络评价分析指向副作用
Why some patients quit a newer insomnia medication
Rutgers 等机构研究者分析2020至2023年间260条 lemborexant(Dayvigo)网络用药评价,约四分之一评价者已停药或计划停药,副作用是最主要的区分因素。停药者中40%提到睡眠瘫痪,其余评价者为15%,生动梦境或噩梦及次日昏沉也更常见。研究者指出网络评价无法反映全部使用者的发生比例,该药两项主要临床试验中睡眠瘫痪发生率低于2/100。
Researchers from Rutgers and other universities analyzed hundreds of online reviews on lemborexant—and learned that about 1 in 4 of the reviewers stopped or planned to stop taking the prescription medication used to treat insomnia.
Insomnia—difficulty falling or staying asleep—affects about 30% of adults, according to prior sleep research. Lemborexant, approved in the U.S. in 2019, belongs to the newest class of insomnia drugs. Rather than broadly sedating the brain like many older sleeping pills, these medicines block signals from orexin, a chemical messenger that helps keep people awake. In clinical trials, lemborexant (sold as Dayvigo) helped people fall asleep faster and stay asleep longer than a placebo.
Ongoing work at Rutgers Brain Health Institute is investigating the potential repurposing of orexin-based sleep medications to treat sleep disturbances in a range of psychiatric conditions, including addiction.
To learn how patients experience the drug in everyday life, researchers from Rutgers Brain Health Institute, Virginia Commonwealth University and the University of Sydney analyzed 260 online reviews of lemborexant, posted between 2020 and 2023. The results of the study are published in the journal Sleep Medicine.
Team members classified 70 of the 260 reviewers as having stopped or planning to stop. These reviewers were less likely to say the drug had helped, yet they were about as likely as everyone else to complain of poor or broken sleep. Side effects most clearly set them apart. Across all reviewers, ratings split sharply. The most common score was 1, followed by 10. Roughly a third of reviewers said the drug meaningfully improved their sleep.
"It feels like I am sleeping naturally like I did once upon a time," one person wrote online about lemborexant, rating it 10 out of 10.
Another person rated the same drug a 1. "Felt paralyzed to move. Wanted to scream and could not make a sound," the reviewer noted. "Was able to touch my husband's arm and waken him. He said he never saw such terror in my eyes."
That person was describing sleep paralysis, a temporary state of being awake but unable to move or speak. Sleep paralysis came up in 40% of reviews from people who stopped or planned to stop, compared with 15% of the rest. Vivid dreams or nightmares were more common, as was next-day grogginess. Many reviewers said side effects drove them to stop. "The dreams [nightmares] are VERY vivid and that's the reason I can no longer take this medication," one wrote.
"What surprised us most was how unsettling some patients found certain side effects," said Abanoub J. Armanious, a pharmacoepidemiologist and neuropsychiatry researcher with the Rutgers Brain Health Institute and lead author of the study. "For these individuals, stopping the medication was not simply about it failing to improve sleep."
One proposed explanation for the nightmares and sleep paralysis involves dreaming sleep, when the brain normally switches off most of the body's muscles. Blocking orexin can increase dreaming sleep, which may let vivid dreams and muscle shutdown spill into waking moments.
"One of the important messages from our study is that lemborexant was reported to work very well for some people," said Morgan James, the senior author of the study, adjunct assistant professor at Rutgers Brain Health Institute and Horizon fellow and senior lecturer at the Brain and Mind Center and School of Psychology at the University of Sydney.
But half of the reviewers reported little or no benefit, and two-thirds mentioned at least one side effect. About 1 in 5 brought up sleep paralysis, and nearly a third described vivid dreams or nightmares.
Not every dream was unwelcome. One reviewer, who rated the drug a 9, looked forward to the "wild crazy dreams."
The researchers emphasized that the numbers can't show how common any of these experiences are among all users, because people with the best or worst experiences are most likely to post. In lemborexant's two main clinical trials, which tracked everyone enrolled, fewer than 2 in 100 participants taking it had sleep paralysis, and about 1 to 3 in 100 reported nightmares or abnormal dreams.
"A clinical trial can tell you how often side effects occur," Armanious said. "It is less equipped to tell you how much that side effect matters to the person living it. A side effect can be rare and still be the reason someone discontinues treatment."
Most reviewers, especially those who stopped or planned to stop, had used the drug for less than a month. Longer-term users generally rated it higher, though the study cannot say why.
The researchers said they hope people will know about these side effects without being alarmed. Anyone taking a prescribed sleep medication should talk with a clinician before stopping or changing it.
"What really stands out is how different people's experiences with this medication can be, which highlights the importance of setting expectations and finding the right treatment for the individual," James said.
Publication details
Abanoub J. Armanious et al., Perceived effectiveness, tolerability, and discontinuation of lemborexant in real-world use: Evidence from online patient reports, Sleep Medicine (2027). DOI: 10.1016/j.sleep.2026.109264
Journal information: Sleep Medicine
Key medical concepts
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Why some patients quit a newer insomnia medication (2026, October 30) retrieved 30 October 2026 from https://medicalxpress.com/news/2026-10-patients-insomnia-medication.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com